Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.57 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 9/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095270 | 0.80 | EGFR (0.74) | EGFRERBB2RETKDR | |
| SCHEMBL1105423 | 0.80 | EGFR (0.74) | EGFRERBB2RETKDR | |
| SCHEMBL4736326 | 0.80 | EGFR (0.67) | EGFRERBB2RETKDR | |
| SCHEMBL1105371 | 0.80 | EGFR (0.67) | EGFRERBB2RETKDR | |
| SCHEMBL1105383 | 0.78 | EGFR (0.75) | EGFRERBB2RETKDR | |
| SCHEMBL1105378 | 0.78 | EGFR (0.71) | EGFRERBB2KDR | |
| SCHEMBL1105407 | 0.78 | EGFR (0.71) | EGFRERBB2KDR | |
| SCHEMBL4733568 | 0.78 | EGFR (0.71) | EGFRERBB2RETKDR | |
| SCHEMBL1105364 | 0.78 | EGFR (0.64) | EGFRERBB2RET | |
| SCHEMBL4737276 | 0.78 | EGFR (0.64) | EGFRERBB2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157412-A1 | Substituted Pyrimidinyl Oxime Kinase Inhibitors | BATTISTA KATHLEEN A (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157412-A1 | Substituted Pyrimidinyl Oxime Kinase Inhibitors | MAP3K2, MAP3K1, MAP3K20 | EGFR 1201/4885ERBB2 124/4885RET 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.